Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).

Kanemura H, Tanizaki J, Matsumoto K, Masuishi T, Isobe T, Kenmotsu H, Sunakawa Y, Shimizu T, Chiba Y, Yamamoto N, Nakagawa K, Hayashi H

Open source

DOI: 10.1016/j.ejca.2026.116684
Published: 2026 May 2
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.116684,
  title = {Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).},
  author = {Kanemura H and Tanizaki J and Matsumoto K and Masuishi T and Isobe T and Kenmotsu H and Sunakawa Y and Shimizu T and Chiba Y and Yamamoto N and Nakagawa K and Hayashi H},
  year = {2026},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2026.116684},
  url = {https://doi.org/10.1016/j.ejca.2026.116684}
}

RIS

TY  - JOUR
TI  - Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).
AU  - Kanemura H
AU  - Tanizaki J
AU  - Matsumoto K
AU  - Masuishi T
AU  - Isobe T
AU  - Kenmotsu H
AU  - Sunakawa Y
AU  - Shimizu T
AU  - Chiba Y
AU  - Yamamoto N
AU  - Nakagawa K
AU  - Hayashi H
PY  - 2026
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2026.116684
UR  - https://doi.org/10.1016/j.ejca.2026.116684
ER  -

APA

H, K., J, T., K, M., T, M., T, I., H, K., Y, S., T, S., Y, C., N, Y., K, N., & H, H. (2026). Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2026.116684

Source records

pubmed · retrieved 2026-09-26T11:14:04.354Z
europe-pmc · retrieved 2026-09-26T11:14:04.370Z